Old Web
English
Sign In
Acemap
>
authorDetail
>
Rodrigo Ruiz-Soto
Rodrigo Ruiz-Soto
GlaxoSmithKline
Medicine
Oncology
Pazopanib
Internal medicine
Cetuximab
3
Papers
31
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer
2015
Investigational New Drugs
Jaafar Bennouna
Marion Deslandres
Hélène Senellart
Cécile de Labareyre
Rodrigo Ruiz-Soto
Claire Wixon
Jeff Botbyl
A. Benjamin Suttle
Jean-Pierre Delord
Show All
Source
Cite
Save
Citations (16)
Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in patients (Pts) with epithelial ovarian cancer (EOC) and other FRa-positive solid tumors.
2014
Journal of Clinical Oncology
Kathleen N. Moore
Joseph Ponte
Patricia LoRusso
Michael J. Birrer
Todd Michael Bauer
Hossein Borghaei
David M. O'Malley
Rodrigo Ruiz-Soto
Robert J. Lutz
Laeeq Malik
Show All
Source
Cite
Save
Citations (15)
Phase I trial (VEG108925) of cetuximab, irinotecan, and pazopanib (GW786034) administered concurrently.
2010
Journal of Clinical Oncology
M. Deslandres
Jean-Pierre Delord
Jaafar Bennouna
F. Ollivier
Hélène Senellart
C. M. de-Labareyre
F. C. Hagobian
Rodrigo Ruiz-Soto
Claire Wixon
Show All
Source
Cite
Save
Citations (0)
1